drugset
Drugs / Vibostolimab/Pembrolizumab
last change Aug 2026 re-read 9 days ago

Vibostolimab/Pembrolizumab

Developed for
renal cell carcinoma
Investigated by
Merck Sharp & Dohme LLC

Trials 1

today NCT04626479 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04626479 Dec 2020 → Aug 2026 renal cell carcinoma Merck Sharp & Dohme LLC Completed No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2024-12-16 Merck Sharp & Dohme LLC Results Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab merck.com ↗
In a pre-planned analysis, both trials met the pre-specified futility criteria for the primary endpoint of overall survival.
2024-08-08 Merck Sharp & Dohme LLC Results Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer merck.com ↗
At a pre-planned analysis, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria.
2024-05-13 Merck Sharp & Dohme LLC Results Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma merck.com ↗
At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.
2023-12-07 Merck Sharp & Dohme LLC Results Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) merck.com ↗
Vibostolimab/pembrolizumab alone did not show an improvement in median PFS compared to docetaxel alone (2.7 months vs. 3.2 months; HR=1.40 [95% CI, 0.96-2.02]; p=0.9622).

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Vibostolimab/Pembrolizumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT04626479 ↗